药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

辉瑞/Astellas的Xtandi降低前列腺癌的扩散风险

2018-02-06 MedSci MedSci原创

辉瑞/Astellas的Xtandi
关注

试验结果显示，与单独使用激素疗法相比，将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险。根据III期PROSPER试验的结果，与非ADT单药治疗的非转移性去势前列腺癌（CRPC）患者相比，Xtandi（enzalutamide）加雄激素剥夺疗法（ADT）将发生转移或死亡的风险降低了71％。主要终点无转移生存期（MFS）的中位数为36.6个月，而接受Xt

试验结果显示，与单独使用激素疗法相比，将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险。

根据III期PROSPER试验的结果，与非ADT单药治疗的非转移性去势前列腺癌（CRPC）患者相比，Xtandi（enzalutamide）加雄激素剥夺疗法（ADT）将发生转移或死亡的风险降低了71％。

主要终点无转移生存期（MFS）的中位数为36.6个月，而接受Xtandi的男性则为36.7个月，而单独使用ADT的患者为14.7个月。

试验数据还显示，接受Xtandi / ADT治疗的患者的PSA进展相对危险度降低了93％，与单独使用ADT相比，首次使用新抗肿瘤治疗的中位时间延长了21.9个月。

"对于非转移性CRPC患者来说，延迟转移发展和进展为晚期前列腺癌存在很高的未满足需求。美国西北大学Robert H. Lurie综合癌症中心的Maha Hussain表示，目前在美国尚未批准对非转移性CRPC患者进行系统性治疗。他将在今年晚些时候的一次医学大会上介绍这些数据。

"在PROSPER试验中，enzalutamide加ADT治疗延缓了转移的发展，与ADT治疗标准相比，如果获得批准，可能为男性提供非转移性CRPC治疗方案。

该公司指出，基于PROSPER研究结果的营销申请已经提交给美国食品和药物管理局（FDA）和欧洲药品管理局（EMA），目前正在考虑进行全面审查。

原文出处：http：//www.pharmatimes.com/news/pfizerastellas_xtandi_cuts_risk_of_prostate_cancer_spread_1220552


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

 


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-06-04 ms24272190615788285182

    #AST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-05-26 lingaifan

    #Xtandi#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-02-08 docwu2019

    #Astellas#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-02-08 yjs木玉

    好好好好好好好好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-02-07 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-02-07 秀红

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1711377, encodeId=ee2f1e1137788, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Mon Jun 04 00:50:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653711, encodeId=97f61653e11e2, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat May 26 10:50:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561951, encodeId=30aa156195104, content=<a href='/topic/show?id=1f95289ea7' target=_blank style='color:#2F92EE;'>#Astellas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2897, encryptionId=1f95289ea7, topicName=Astellas)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Feb 08 12:50:00 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286112, encodeId=742028611213, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Thu Feb 08 05:05:09 CST 2018, time=2018-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286057, encodeId=250628605ed5, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Feb 07 22:53:42 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285830, encodeId=d2c528583070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Feb 07 06:09:31 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285774, encodeId=e59a285e7480, content=试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险., beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Feb 06 23:40:31 CST 2018, time=2018-02-06, status=1, ipAttribution=)]
    2018-02-06 有备才能无患

    试验结果显示.与单独使用激素疗法相比.将辉瑞和Astellas制药公司的Xtandi用于激素治疗显着降低了前列腺癌扩散的风险.

    0